Molecular Correlates of Clinical Response and Resistance to Atezolizumab in Combination with Bevacizumab in Advanced Hepatocellular Carcinoma

Researchers reported integrated molecular analyses of tumor samples from 358 patients with hepatocellular carcinoma enrolled in the GO30140 Phase Ib or IMbrave150 Phase III trial and treated with atezolizumab combined with bevacizumab, atezolizumab alone, or sorafenib.